Compositions for organ preservation
View Patent ↗The invention relates to the field of preserving the viability of organs or tissues to be transplanted into a recipient in need of such a transplantation. In particular, the invention relates to use of a sigma 1 receptor agonist compound in preservation solutions and preservation solutions comprising a sigma 1 receptor agonist compound.
1. A method for reducing or delaying cellular damage that occurs during ex vivo storage of a transplantable whole or partial organ or tissue, the method comprising
(i) contacting the whole or partial organ or tissue ex vivo with a composition comprising an amount of a sigma 1 receptor (S1R) agonist compound effective in reducing or delaying cellular damage of said transplantable whole or partial organ or tissue during ex vivo storage and a physiologically acceptable solution suitable for ex vivo organ preservation,
(ii) maintaining the transplantable whole or partial organ or tissue ex vivo in said composition before transplantation,
wherein the transplantable whole or partial organ or tissue is maintained at a temperature of from 0° C. to 10° C., and
wherein the S1R agonist compound has the following formula I′:
wherein
Q 1 is H, halogen, pseudo-halogen, C(1-4) alkyl optionally substituted with 1, 2, 3 or 4 halogen(s), C(1-3) alkoxy, C(6-10) aryl, optionally substituted with 1, 2, 3 or 4 halogen(s),
Q 2 is H, halogen, pseudo-halogen or C(1-3) alkoxy,
X is O, CH 2 , ethylene or carbonyl (CO), amide or not present,
or X has the formula
wherein R 6 is selected from the group consisting of a hydroxyl, substituted or unsubstituted C(1-6) alkyl, C(1-6) alkoxy, or C(1-6) alkoxyalkyl, and C(5-10) aryl,
or X has the formula
wherein W is —CH— or carbonyl (—CO—) or W is not present, and
R 6 and R 6 ′ are independently substituted or unsubstituted C(1-6) alkyl, C(1-6) alkyloxy, C(1-6) alkoxyalkyl, C(1-6) alkyloxy carbonyl, or at least one of R 6 and R 6 ′ is a C(5-10) aryl,
or R 6 and R 6 ′ together form a C(4-7) cycloalkyl,
or X has the formula
wherein R 6 is selected from a substituted or unsubstituted C(1-6) alkyl, C(1-6) alkoxy, or C(5-10) aryl,
Y is CH, N or O, —O—CH 2 —CH 2 —O— or not present
wherein
if Y is O then R 4 is not present,
if Y is N then R 4 is H, or a C(1-3) alkyl or C(1-3) alkenyl, or R 4 and R 1 together with Y, N and the carbon atoms between them form a C(5-7) heterocyclic ring,
if Y is CH then R 4 is selected from a H, substituted or unsubstituted C(1-4) alkyl, C(1-4) alkoxy and C(5-10) aryl, or R 4 and R 1 together with Y, N and the carbon atoms between them form a C(5-7) heterocyclic ring,
R 3 is selected from H, a substituted or unsubstituted C(1-6) alkyl, C(1-6) alkoxy, C(5-10) aryl, or
R 3 and the —X—Y—C2- alkyl moiety, via R 6 , may form a saturated or partially unsaturated 6 to 8 membered cycloalkyl or 6 to 8 membered heterocycloalkyl comprising 0 to 3 heteroatom(s), or
R 3 and the —X—Y—C2- alkyl moiety, via R 6 , may form a substituted or unsubstituted C(7-14) polycyclic aryl or C(7-14) polycyclic heteroaryl or C(7-14) cycloalkylaryl, or
R 3 and the —Y—C2- alkyl moiety, via R 4 , may form a saturated or partially unsaturated 6 to 8 membered cycloalkyl or 6 to 8 membered heterocycloalkyl comprising 0 to 3 heteroatom, or an alkylaryl,
R 5 is H, C(1-3) alkyl or C(1-3) alkyloxy or
R 5 and R 6 together with carbon atoms which they are attached to form a 3, 4, 5 or 6 membered saturated or unsaturated ring, said ring optionally comprising a heteroatom,
R 1 and R 2 are independently H or a C(1-6) alkyl, or
R 1 and R 2 form a 5 or 6 membered, saturated or unsaturated ring,
said ring optionally comprising a heteroatom, or
said ring being optionally a substituted or unsubstituted piperidine ring, or
R 1 is a C(2-4) alkylene and together with Y and N and the carbon atoms between Y and N form a heterocyclic ring, and
R 2 is a C(1-6) alkyl, C(5-10) aryl or C(7-10) aralkyl,
or R 2 is a C(2-4) alkylene and together with the N form a heterocyclic ring,
or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 , wherein the organ is selected from heart, lung, abdominal organs, or cornea.
3. The method according to claim 1 , wherein the organ is the kidney or the tissue is renal tissue.
4. The method according to claim 1 , wherein the organ is the liver or the tissue is hepatic tissue.
5. The method according to claim 1 , wherein
Q 1 is H, halogen, pseudo-halogen, C(1-4) alkyl optionally substituted with 1, 2, 3 or 4 halogen(s), C(1-3) alkoxy, C(6-10) aryl, optionally substituted with 1, 2, 3 or 4 halogen(s),
Q 2 is H, halogen, pseudo-halogen or C(1-3) alkoxy,
X is O, CH 2 , ethylene or carbonyl (CO), amide or not present,
or X has the formula
wherein
W is —CH— or carbonyl (—CO—), and
R 6 and R 6 ′ are independently substituted or unsubstituted C(1-6) alkyl, C(1-6) alkyloxy, C(1-6) alkoxy C(1-6) alkyl, C(1-6) alkyloxy carbonyl or at least one of R 6 and R 6 ′ is a C(5-10) aryl,
or R 6 and R 6 ′ together form a C(4-7) cycloalkyl,
or X has the formula
wherein
R 6 is selected from a substituted or unsubstituted C(1-6) alkyl, C(1-6) alkoxy, C(1-6) alkoxy C(1-6) alkyl or C(1-2) alkoxy C(1-6) alkyl or C(1-6) alkoxyalkyl, C(1-6) alkyloxy carbonyl or C(5-10) aryl,
Y is CH, N or O, —O—CH 2 —CH 2 —O— or not present
wherein
if Y is O then R 4 is not present,
if Y is N then R 4 is H, or a C(1-3) alkyl or C(1-3) alkenyl,
if Y is CH then R 4 is selected from a H, substituted or unsubstituted C(1-4) alkyl, C(1-4) alkoxy and C(5-10) aryl,
R 3 is selected from H, a substituted or unsubstituted C(1-6) alkyl, C(1-6) alkoxy, C(1-2) alkoxy C(1-6) alkyl or C(1-6) alkoxyalkyl, C(5-10) aryl
R 5 is H, C(1-3) alkyl or C(1-3) alkyloxy
R 1 and R 2 are independently H or a C(1-6) alkyl, or
R 1 and R 2 form a 5 or 6 membered, saturated or unsaturated, said ring optionally comprising a heteroatom, or
said ring being optionally a substituted or unsubstituted piperidine ring.
6. The method according to claim 5 , wherein
Q 1 is H, halogen, pseudo-halogen, C(1-2) alkyl optionally substituted with 1, 2, 3 or 4 halogen(s), C(1-2) alkoxy, C(5-6) aryl, optionally substituted with 1, 2, 3 or 4 halogen(s),
Q 2 is H, halogen or pseudo-halogen,
X is O, or
X has the formula
wherein
W is —CH— or carbonyl (—CO—), and
R 6 and R 6 ′ are independently substituted or unsubstituted C(1-3) alkyl, C(1-3) alkoxy, C(1-2) alkoxy C(1-6) alkyl, C(1-4) alkyloxycarbonyl or at least one of R 6 and R 6 ′,
or R 6 and R 6 ′ together form a C(4-6) cycloalkyl,
or X has the formula
wherein
R 6 is selected from C(1-3) alkyl, C(1-3) alkoxy, C(1-4) alkoxy C(1-6) alkyl or C(1-6) alkoxyalkyl, C(1-4) alkyloxycarbonyl or C(5-6) aryl,
Y is O or —O—CH 2 —CH 2 —O—
wherein
R 4 is not present,
R 3 is selected from H, C(1-4) alkyl, C(1-4) alkoxy, C(1-2) alkoxy C(1-6) alkyl, C(1-6) alkoxyalkyl, or C(5-6) aryl
R 5 is H, C(1-3) alkyl or C(1-3) alkyloxy
R 1 and R 2 are independently H or a methyl or ethyl, or
R 1 and R 2 form a 5 or 6 membered, saturated or unsaturated ring, said ring optionally comprising a heteroatom, or
said ring being optionally a substituted or unsubstituted piperidine ring.
7. The method according to claim 1 , wherein said S1R agonist compound has the following formula II:
wherein
Q 1 is a Cl or F or a methyl substituted with halogen selected from CH 2 F, CHF 2 CF 3 , CH 2 Cl, CHCl 2 , CCl 3 , or methoxy
Q 2 is H, Cl or F,
R 6 is selected from a substituted or unsubstituted C(1-3) alkyl, C(1-3) alkoxy, C(1-2) alkoxy C(1-6) alkyl, C(5-6) aryl,
Y is O
R 4 is not present,
R 3 is H, methyl or ethyl,
R 5 is H, methyl or ethyl,
R 1 and R 2 are independently H, methyl or ethyl,
or a pharmaceutically acceptable salt thereof.
8. The method according to claim 7 , wherein
Q 1 is a methyl substituted with halogen selected from CHF 2 , CF 3 , CHCl 2 and CCl 3 ,
Q 2 is H,
R 6 is selected from a substituted or unsubstituted C(1-2) alkoxy C(2-5) alkyl,
Y is O,
R 4 is not present,
R 3 is H or methyl,
R 5 is H, methyl or ethyl,
R 1 and R 2 are independently H, methyl or ethyl,
or a pharmaceutically acceptable salt thereof.
9. The method according to claim 1 , wherein the S1R agonist compound is selective for S1 receptors over S2 receptors.
10. The method according to claim 1 , wherein the S1R agonist compound is fluvoxamine.
11. The method according to claim 3 , wherein the S1R agonist compound is fluvoxamine.
12. A method for reducing or delaying cellular damage that occurs during ex vivo storage of a transplantable whole or partial organ or tissue, the method comprising
(i) contacting the transplantable whole or partial organ or tissue ex vivo with a composition comprising an amount of a sigma 1 receptor (S1R) agonist compound effective in reducing or delaying cellular damage of said transplantable whole or partial organ or tissue during ex vivo storage and a physiologically acceptable solution suitable for ex vivo organ preservation,
(ii) maintaining the transplantable whole or partial organ or tissue ex vivo in said composition before transplantation,
wherein the S1R agonist compound has the following formula I′:
wherein
Q 1 is H, halogen, pseudo-halogen, C(1-4) alkyl optionally substituted with 1, 2, 3 or 4 halogen(s), C(1-3) alkoxy, C(6-10) aryl, optionally substituted with 1, 2, 3 or 4 halogen(s),
Q 2 is H, halogen, pseudo-halogen or C(1-3) alkoxy,
X is O, CH 2 , ethylene or carbonyl (CO), amide or not present,
or X has the formula
wherein R 6 is selected from the group consisting of a hydroxyl, substituted or unsubstituted C(1-6) alkyl, C(1-6) alkoxy, or C(1-6) alkoxyalkyl, and C(5-10) aryl,
or X has the formula
wherein W is —CH— or carbonyl (—CO—) or W is not present, and
R 6 and Re are independently substituted or unsubstituted C(1-6) alkyl, C(1-6) alkyloxy, C(1-6) alkoxyalkyl, C(1-6) alkyloxy carbonyl, or at least one of R 6 and R 6 ′ is a C(5-10) aryl,
or R 6 and R 6 ′ together form a C(4-7) cycloalkyl,
or X has the formula
wherein R 6 is selected from a substituted or unsubstituted C(1-6) alkyl, C(1-6) alkoxy, or C(5-10) aryl,
Y is CH, N or O, —O—CH 2 —CH 2 —O— or not present
wherein
if Y is O then R 4 is not present,
if Y is N then R 4 is H, or a C(1-3) alkyl or C(1-3) alkenyl, or R 4 and R 1 together with Y, N and the carbon atoms between them form a C(5-7) heterocyclic ring,
if Y is CH then R 4 is selected from a H, substituted or unsubstituted C(1-4) alkyl, C(1-4) alkoxy and C(5-10) aryl, or R 4 and R 1 together with Y, N and the carbon atoms between them form a C(5-7) heterocyclic ring,
R 3 is selected from H, a substituted or unsubstituted C(1-6) alkyl, C(1-6) alkoxy, C(5-10) aryl, or
R 3 and the —X—Y—C2- alkyl moiety, via R 6 , may form a saturated or partially unsaturated 6 to 8 membered cycloalkyl or 6 to 8 membered heterocycloalkyl comprising 0 to 3 heteroatom(s), or
R 3 and the —X—Y—C2- alkyl moiety, via R 6 , may form a substituted or unsubstituted C(7-14) polycyclic aryl or C(7-14) polycyclic heteroaryl or C(7-14) cycloalkylaryl, or
R 3 and the —Y—C2- alkyl moiety, via R 4 , may form a saturated or partially unsaturated 6 to 8 membered cycloalkyl or 6 to 8 membered heterocycloalkyl comprising 0 to 3 heteroatom, or an alkylaryl,
R 5 is H, C(1-3) alkyl or C(1-3) alkyloxy or
R 5 and R 6 together with carbon atoms which they are attached to form a 3, 4, 5 or 6 membered saturated or unsaturated ring, said ring optionally comprising a heteroatom,
R 1 and R 2 are independently H or a C(1-6) alkyl, or
R 1 and R 2 form a 5 or 6 membered, saturated or unsaturated ring,
said ring optionally comprising a heteroatom, or
said ring being optionally a substituted or unsubstituted piperidine ring, or
R 1 is a C(2-4) alkylene and together with Y and N and the carbon atoms between Y and N form a heterocyclic ring, and
R 2 is a C(1-6) alkyl, C(5-10) aryl or C(7-10) aralkyl,
or R 2 is a C(2-4) alkylene and together with the N form a heterocyclic ring,
or a pharmaceutically acceptable salt thereof,
wherein the organ is the kidney and the tissue is renal tissue,
wherein cellular damage of the kidney or the renal tissue is reduced or delayed, as indicated by a decrease of the tubular lumen area dilatation or any one of a decreased level of serum creatinine, decreased level of blood urea nitrogen, decreased level of blood KIM1, decreased level of blood MCP-1, decreased level of blood NGAL and increased glomerular filtration rate, as compared to the corresponding marker in an organ stored under identical conditions and in a preservation solution having the same composition but not comprising the S1R agonist compound.
13. The method according to claim 1 , wherein the transplantable whole or partial organ or tissue is stored for at least 6 hours after the contacting and before the transplantation.
14. The method according to claim 12 , wherein the kidney or renal tissue is maintained at a temperature of from 0° C. to 10° C.
15. The method according to claim 12 , wherein
Q 1 is H, halogen, pseudo-halogen, C(1-4) alkyl optionally substituted with 1, 2, 3 or 4 halogen(s), C(1-3) alkoxy, C(6-10) aryl, optionally substituted with 1, 2, 3 or 4 halogen(s),
Q 2 is H, halogen, pseudo-halogen or C(1-3) alkoxy,
X is O, CH 2 , ethylene or carbonyl (CO), amide or not present,
or X has the formula
wherein
W is —CH— or carbonyl (—CO—), and
R 6 and R 6 ′ are independently substituted or unsubstituted C(1-6) alkyl, C(1-6) alkyloxy, C(1-6) alkoxy C(1-6) alkyl, C(1-6) alkyloxy carbonyl or at least one of R 6 and R 6 ′ is a C(5-10) aryl,
or R 6 and R 6′ together form a C(4-7) cycloalkyl,
or X has the formula
wherein
R 6 is selected from a substituted or unsubstituted C(1-6) alkyl, C(1-6) alkoxy, C(1-6) alkoxy C(1-6) alkyl or C(1-2) alkoxy C(1-6) alkyl or C(1-6) alkoxyalkyl, C(1-6) alkyloxy carbonyl or C(5-10) aryl,
Y is CH, N or O, —O—CH 2 —CH 2 —O— or not present
wherein
if Y is O then R 4 is not present,
if Y is N then R 4 is H, or a C(1-3) alkyl or C(1-3) alkenyl,
if Y is CH then R 4 is selected from a H, substituted or unsubstituted C(1-4) alkyl, C(1-4) alkoxy and C(5-10) aryl,
R 3 is selected from H, a substituted or unsubstituted C(1-6) alkyl, C(1-6) alkoxy, C(1-2) alkoxy C(1-6) alkyl or C(1-6) alkoxyalkyl, C(5-10) aryl
R 5 is H, C(1-3) alkyl or C(1-3) alkyloxy
R 1 and R 2 are independently H or a C(1-6) alkyl, or
R 1 and R 2 form a 5 or 6 membered, saturated or unsaturated, said ring optionally comprising a heteroatom, or
said ring being optionally a substituted or unsubstituted piperidine ring.
16. The method according to claim 12 , wherein
Q 1 is H, halogen, pseudo-halogen, C(1-2) alkyl optionally substituted with 1, 2, 3 or 4 halogen(s), C(1-2) alkoxy, C(5-6) aryl, optionally substituted with 1, 2, 3 or 4 halogen(s),
Q 2 is H, halogen or pseudo-halogen,
X is O, or
X has the formula
wherein
W is —CH— or carbonyl (—CO—), and
R 6 and R 6 ′ are independently substituted or unsubstituted C(1-3) alkyl, C(1-3) alkoxy, C(1-2) alkoxy C(1-6) alkyl, C(1-4) alkyloxycarbonyl or at least one of R 6 and R 6′ ,
or R 6 and Re together form a C(4-6) cycloalkyl,
or X has the formula
wherein
R 6 is selected from C(1-3) alkyl, C(1-3) alkoxy, C(1-4) alkoxy C(1-6) alkyl or C(1-6) alkoxyalkyl, C(1-4) alkyloxycarbonyl or C(5-6) aryl,
Y is O or —O—CH 2 —CH 2 —O—
wherein
R 4 is not present,
R 3 is selected from H, C(1-4) alkyl, C(1-4) alkoxy, C(1-2) alkoxy C(1-6) alkyl, C(1-6) alkoxyalkyl, or C(5-6) aryl
R 5 is H, C(1-3) alkyl or C(1-3) alkyloxy
R 1 and R 2 are independently H or a methyl or ethyl, or
R 1 and R 2 form a 5 or 6 membered, saturated or unsaturated ring, said ring optionally comprising a heteroatom, or
said ring being optionally a substituted or unsubstituted piperidine ring.
17. The method according to claim 12 , wherein the S1R agonist compound has the following formula II:
wherein
Q 1 is a Cl or F or a methyl substituted with halogen selected from CH 2 F, CHF 2 CF 3 , CH 2 Cl, CHCl 2 , CCl 3 , or methoxy
Q 2 is H, Cl or F,
R 6 is selected from a substituted or unsubstituted C(1-3) alkyl, C(1-3) alkoxy, C(1-2) alkoxy C(1-6) alkyl, C(5-6) aryl,
Y is O
R 4 is not present,
R 3 is H, methyl or ethyl,
R 5 is H, methyl or ethyl,
R 1 and R 2 are independently H, methyl or ethyl,
or a pharmaceutically acceptable salt thereof.
18. The method according to claim 12 , wherein
Q 1 is a methyl substituted with halogen selected from CHF 2 , CF 3 , CHCl 2 and CCl 3 ,
Q 2 is H,
R 6 is selected from a substituted or unsubstituted C(1-2) alkoxy C(2-5) alkyl,
Y is O,
R 4 is not present,
R 3 is H or methyl,
R 5 is H, methyl or ethyl,
R 1 and R 2 are independently H, methyl or ethyl.
19. The method according to claim 12 , wherein the S1R agonist compound is selective for S1 receptors over S2 receptors.
20. The method according to claim 12 , wherein the S1R agonist compound is fluvoxamine.
21. The method according to claim 1 , wherein
treatment of a donor or recipient of the tissue or organ with the S1R agonist compound is avoided,
a level of one or more marker(s) selected from the group consisting of number of apoptic cells, expression level of IL-6, and expression level of IL-1α is decreased as compared to a corresponding marker in an organ or tissue stored under identical conditions and in a preservation solution having the same composition but not comprising the S1R agonist compound, and
the organ or tissue showed at least 25% less tissue damage as demonstrated by histologic assay after at least 1.5 fold longer preservation time than organs or tissues stored in the same preservation solution not containing the S1R agonist compound.